title: Excretion of afobazole and its metabolites with urine and feces in rats.
abstract: The amount of afobazole and identified metabolites was measured in the urine and feces of rats after intraperitoneal and peroral administration of the drug in a dose of 25 mg/kg. Over 1 day after intraperitoneal or peroral treatment with afobazole, urine and feces contained 0.1% initial compound (from administered dose) and 42.1% metabolites.
authors.affiliation: V. V. Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
authors.forename: A O
authors.initials: AO
authors.lastname: Viglinskaya
authors.forename: G B
authors.initials: GB
authors.lastname: Kolyvanov
authors.forename: A A
authors.initials: AA
authors.lastname: Litvin
authors.forename: V P
authors.initials: VP
authors.lastname: Zherdev
authors.forename: S B
authors.initials: SB
authors.lastname: Seredenin
mesh_terms: D000818:Animals; D021461:Animals, Outbred Strains; D014151:Anti-Anxiety Agents / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics / Q000652:urine; D001562:Benzimidazoles / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005243:Feces / Q000737:chemistry*; D008297:Male; D009025:Morpholines / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine*; D051381:Rats; D013997:Time Factors
chemical_list: C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D014151:Anti-Anxiety Agents; D001562:Benzimidazoles; D009025:Morpholines